Bayer’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure
Merck, also recognized as MSD in regions beyond the United States and Canada, has officially announced that the FDA has approved for the use of KEYTRUDA, Merck's anti-PD-1 therapy, in conjunction with chemoradiotherapy (CRT) for treating patients diagnosed with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. This approval is grounded in findings from the Phase III KEYNOTE-A18 trial, wherein the combination of KEYTRUDA and CRT displayed a notable enhancement in progression-free survival (PFS), resulting in a 41% reduction in the risk of disea...